Showing results (721-730 of 4,512) with videos related to

Sort By:
Pageof 452
Future Oncology (London, England)|November 26, 2021
Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisLecai Xiong, Yi Cai, Xiao Zhou, et al.
Future Oncology (London, England)|January 18, 2022
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burdenCharles Peterfy, Yan Chen, Peter Countryman, et al.
Future Oncology (London, England)|November 15, 2021
DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapyAndrea R Filippi, Rafał Dziadziuszko, Maria Rosario García Campelo, et al.
Future Oncology (London, England)|November 16, 2021
The impact of the ALK fusion variant on clinical outcomes in EML4-ALK patients with NSCLC: a systematic review and meta-analysisShasha Wang, Rongrong Luo, Yuankai Shi, et al.
Future Oncology (London, England)|November 17, 2021
Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myelomaTomer Mark, Angelica Falkenstein, Jonathan Kish
Future Oncology (London, England)|November 29, 2021
Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS studyKatie Mycock, Lin Zhan, Kieran Hart, et al.
Future Oncology (London, England)|December 10, 2021
The concept of oligometastatic disease in gastric cancer: reality or fiction?Serge Kassar, Ramy Samaha, Rany Aoun, et al.
Future Oncology (London, England)|November 15, 2021
Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003Tae Won Kim, Julien Taieb, Ellen B Gurary, et al.
Future Oncology (London, England)|December 8, 2021
Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancerYu Mei, Min Shi, Zhenglun Zhu, et al.
Future Oncology (London, England)|January 6, 2022
Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancerJianbo Zhu, Guangpeng Chen, Kai Niu, et al.
Pageof 452